Assessment of immune function with a cytokine release assay predicts 90-day survival in people with alcohol-related hepatitis
The American Journal of the Medical Sciences · 2026-11
DOI: 10.1016/j.amjms.2026.11.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of the Medical Sciences, 2026-11. Verfasst von Paula Boeira und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology Research Group, Faculty of Health, University of Plymouth, 16 Research Way, Plymouth, PL6 8BU, United Kingdom. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Research and Innovation Medical Research Council.
Abstract (Originalsprache)
BACKGROUND: Alcohol-related hepatitis (AH) has a 30% 90-day mortality. More accurate predictors of mortality and infection are needed to guide patient management. Quantiferon Monitor (QFM), an interferon (IFN)-γ release assay, measures global immune function and predicted 90-day mortality and incident infection in patients with AH in a preliminary study. We aimed to validate these findings in a multicenter study. METHODS: Consecutive patients with AH (bilirubin >50 µmol/L, coagulopathy and harmful alcohol use [40g/60 g ethanol/day in females/males]) recruited to the Multicentre Cohort of AH study at two sites, took part. Outcomes of survival and infection were collected up to day 90. A blood sample was obtained at baseline and QFM was performed according to manufacturer's instructions. RESULTS: 46 participants were recruited; 61% male, MELD 20.8. QFM was higher in survivors compared to non-survivors at day 90 (74.1 vs 4.7 IU/mL; p < 0.0001; AUROC 0.85 [0.71-1.0]). Negative predictive value of QFM for 90-day mortality was 77%. MELD performed similarly but with a negative predictive value of 50% (MELD threshold 21). Neither QFM nor MELD predicted incident infection. CONCLUSIONS: Global immune function measured by QFM accurately predicts 90-day mortality in patients with AH. It has higher predictive accuracy for 90-day mortality than MELD. However, it cannot reliably predict incident infection. QFM could be integrated into clinical management pathways as a decision tool to guide treatment options.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hepatology Research Group, Faculty of Health, University of Plymouth, 16 Research Way, Plymouth, PL6 8BU, United Kingdom.
- Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, Du Cane Road, London, W12 0NN, United Kingdom.
- South West Liver Unit, University Hospitals Plymouth NHS Trust, Derriford Road, Plymouth, PL6 8DH, United Kingdom.
- Hepatology Research Group, Faculty of Health, University of Plymouth, 16 Research Way, Plymouth, PL6 8BU, United Kingdom; South West Liver Unit, University Hospitals Plymouth NHS Trust, Derriford Road, Plymouth, PL6 8DH…
Förderung
- UK Research and Innovation Medical Research Council
Zitieren
APA
Boeira, P., Tan, H., Sultana, A., Avades, T., Thursz, M., & Dhanda, A. (2026). Assessment of immune function with a cytokine release assay predicts 90-day survival in people with alcohol-related hepatitis. The American Journal of the Medical Sciences. https://doi.org/10.1016/j.amjms.2026.11.005
Vancouver
Boeira P, Tan H, Sultana A, Avades T, Thursz M, Dhanda A. Assessment of immune function with a cytokine release assay predicts 90-day survival in people with alcohol-related hepatitis. The American Journal of the Medical Sciences. 2026. doi:10.1016/j.amjms.2026.11.005
BibTeX
@article{Boeira2026,
author = {Boeira, Paula and Tan, Huey and Sultana, Ayesha and Avades, Tamar and Thursz, Mark and Dhanda, Ashwin},
title = {Assessment of immune function with a cytokine release assay predicts 90-day survival in people with alcohol-related hepatitis},
journal = {The American Journal of the Medical Sciences},
year = {2026},
doi = {10.1016/j.amjms.2026.11.005}
}
EUVIMED